Inhibition of PTPN2 can alleviate the inhibition of the JAK/STAT pathway and promote tumor susceptibility to CD8+ T cells dependent on IFN-γ, thereby further amplifying the adaptive immune response (38). This evidence concerns the gene CD8A and neoplasm.